Akèy › Leksemi biphenotipik egi › New York › New York City
Etid klinik pou Leksemi biphenotipik egi nan New York City, NY
10 etid pou Leksemi biphenotipik egi ap chèche patisipan nan sit nan ak bò kote New York City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Ap rekriteFaz 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Ap rekriteFaz 1/2
- Montefiore Medical Center, New York
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Ap rekriteFaz 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai Hospital, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- ak 2 plis
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Ap rekriteFaz 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Ap rekriteFaz 1
- Memorial Sloan- Kettering Cancer Center, New York
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Ap rekriteFaz 2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Study of Revumenib and Mezigdomide in People With Leukemia
Ap rekriteFaz 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Ap rekriteFaz 1
- Children's Hospital New York-Presbyterian, New York
- Memorial Sloan Kettering Cancer Center, New York
Etid Leksemi biphenotipik egi nan lòt vil
- Seattle, WA15 etid
- Houston, TX11 etid
- Atlanta, GA9 etid
- Durham, NC8 etid
- Memphis, TN7 etid
- Chicago, IL7 etid
- Baldwin Park, CA6 etid
- Dallas, TX6 etid
- Los Angeles, CA6 etid
- Charlotte, NC6 etid
- Aurora, CO6 etid
- Philadelphia, PA6 etid
Lòt etid nan New York City
- Kansè nan tete137 etid
- Kansè Poumon ki pa ti selil121 etid
- Kansè (tout kalite)110 etid
- Kansè pwostat102 etid
- Kansè Metastatik93 etid
- Kansè kolorektal78 etid
- Kansè ovè70 etid
- Kansè pankreyas60 etid
- Myelom Miltip60 etid
- Kansè poumon60 etid
- Kansè Endomèt52 etid
- Ensifizyans kadyak51 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 7, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.